Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott P Rigby

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Medical Economics|April 12, 2003
We fired our biggest payerScott P Rigby
Medical Economics|September 27, 2002
We're not leaving $250,000 on the table anymoreScott P Rigby
Cardiovascular Drugs and Therapy|April 9, 2014
Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitusRobert S Rosenson, Scott P Rigby, Michael R Jones, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 1, 2009
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapyScott P Rigby, Yehuda Handelsman, Yu-Ling Lai, et al.
Nature Medicine|August 11, 2022
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trialStephen J Nicholls, Marc Ditmarsch, John J Kastelein, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 19, 2019
Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKDAndrew S Allegretti, Wenbin Zhang, Wenjiong Zhou, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Medical Economics|April 12, 2003
We fired our biggest payerScott P Rigby
Medical Economics|September 27, 2002
We're not leaving $250,000 on the table anymoreScott P Rigby
Cardiovascular Drugs and Therapy|April 9, 2014
Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitusRobert S Rosenson, Scott P Rigby, Michael R Jones, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 1, 2009
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapyScott P Rigby, Yehuda Handelsman, Yu-Ling Lai, et al.
Nature Medicine|August 11, 2022
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trialStephen J Nicholls, Marc Ditmarsch, John J Kastelein, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 19, 2019
Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKDAndrew S Allegretti, Wenbin Zhang, Wenjiong Zhou, et al.
Pageof 1